Edition:
United Kingdom

Natco Pharma Ltd (NATP.NS)

NATP.NS on National Stock Exchange of India

744.40INR
10:25am GMT
Change (% chg)

Rs10.90 (+1.49%)
Prev Close
Rs733.50
Open
Rs740.00
Day's High
Rs749.00
Day's Low
Rs738.15
Volume
110,344
Avg. Vol
227,829
52-wk High
Rs1,050.00
52-wk Low
Rs636.00

Latest Key Developments (Source: Significant Developments)

Natco Pharma Says To Consider Buy-Back Of Equity Shares Of Co And Related Matters
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Natco Pharma Ltd ::SAYS TO CONSIDER BUY-BACK OF EQUITY SHARES OF COMPANY AND RELATED MATTERS.  Full Article

Panacea Biotec Enters Into Agreement With Natco Pharma And Breckenridge Pharma
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Panacea Biotec Ltd ::SAYS ENTERED INTO TRIPARTITE AGREEMENT WITH NATCO PHARMA AND BRECKENRIDGE PHARMACEUTICAL.AGREEMENT FOR THE MANUFACTURE AND SUPPLY OF AZACITIDINE INJECTION FOR THE U.S. MARKET.  Full Article

India's Natco Pharma June Qtr Consol Profit Rises
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Natco Pharma Ltd ::JUNE QUARTER CONSOL NET PROFIT 1.82 BILLION RUPEES VERSUS PROFIT 940 MILLION RUPEES YEAR AGO.JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 5.39 BILLION RUPEES VERSUS 4.45 BILLION RUPEES YEAR AGO.  Full Article

India's Natco Pharma March-Qtr Consol Profit Rises
Wednesday, 23 May 2018 

May 23 (Reuters) - Natco Pharma Ltd ::MARCH QUARTER CONSOL PROFIT 3 BILLION RUPEES VERSUS PROFIT 1.77 BILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 7.68 BILLION RUPEES VERSUS 5.78 BILLION RUPEES YEAR AGO.  Full Article

Natco Pharma Launches Tafnat, Tenofovir Alafenamide Tablets In India
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Natco Pharma Ltd ::SAYS NATCO LAUNCHES TAFNAT, TENOFOVIR ALAFENAMIDE TABLETS, FOR TREATMENT OF CHRONIC HEPATITIS B, IN INDIA.  Full Article

Natco Pharma says Alvogen gets approval ‍​for generic oseltamivir phosphate powder for oral suspension
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Natco Pharma Ltd :Marketing partner Alvogen gets final approval ‍​for generic equivalent to oseltamivir phosphate powder for oral suspension in U.S..  Full Article

India's Natco Pharma Sept-qtr consol profit up about 28 pct
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Natco Pharma Ltd :Sept quarter consol net profit 848 million rupees versus profit of 665 million rupees last year.Consensus forecast for Sept quarter consol net profit was 811.5 million rupees.Sept quarter consol revenue from operations 4.27 billion rupees versus 4.68 billion rupees last year.Says approved raising of funds worth up to 15 billion ‍​rupees‍​.Says approved equity participation not exceeding 75 million rupees in OMRV Hospitals Pvt.  Full Article

Natco Pharma Dec-qtr consol profit soars
Tuesday, 14 Feb 2017 

Natco Pharma Ltd : Dec quarter consol net profit 1.95 billion rupees . Natco pharma ltd consensus forecast for dec quarter consol net profit was 818.4 million rupees . Dec quarter consol net sales 6.43 billion rupees . Declared second interim dividend of inr 6 per share .Consol net profit in dec quarter last year was 369.3 million rupees as per ind-as; consol net sales was 2.75 billion rupees.  Full Article

Photo

Exclusive - With U.S. trade under a cloud, China opens to Indian pharma

NEW DELHI China is preparing to give swift regulatory approvals to India-manufactured drugs, the head of an Indian export promotion group said, as Beijing looks for new commercial partners ahead of what could be a protracted trade war with the United States.